These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: N-terminal pro-B-type natriuretic peptide (NT-proBNP) assessment in the first year after renal transplantation and its relationship with graft function and left ventricular hypertrophy.
    Author: Slubowska K, Sadowska A, Kwiatkowski A, Durlik M.
    Journal: Transplant Proc; 2014 Oct; 46(8):2729-32. PubMed ID: 25380904.
    Abstract:
    BACKGROUND: NT-proBNP is a natriuretic neurohormone released mainly from ventricular cardiomyocytes in conditions of volumetric or pressure overload; it is suitable for use as a marker of left ventricular hypertrophy (LVH), a common disorder in renal transplant recipients. The study objective here was to assess NT-proBNP levels in the 1st year after renal transplantation (RT) and its relationship with graft function and LVH. METHODS: Sixty patients (age, 49 ± 16.9 y; male, 58%) were subjected to prospective 1-year follow-up. Basic blood tests and NT-proBNP level measurements were performed twice (in the early period and at 1 year after transplantation). Cardiac echography was performed in 40 patients. LVH was diagnosed when left ventricular mass index was >95 g/m(2) in women and >115 g/m(2) in men. Statistical analyses were performed with the use of the R Package. RESULTS: At 1 year after RT, the NT-proBNP level decreased >2-fold compared with the early period (median 171 pg/mL [interquartile range (IQR), 104.5-283] vs 368 pg/mL[IQR, 170-629]; P = .00008). In the early post-transplantation period, NT-proBNP correlated with the patient's age, body mass index, estimated glomerular filtration rate (eGFR), and left ventricular end-diastolic dimension, and at 1 year after transplantation its correlation with the eGFR range (patients with eGFR ≥60 mL min(-1) 1.73 m(-2) had significantly lower NT-proBNP levels than those with eGFR <60 mL min(-1) 1.73 m(-2)), with age,and with ejection fraction was found. Patients with LVH had higher NT-proBNP levels than those without LVH in the early period (median 511 pg/mL [IQR, 190-736] vs 380 pg/mL [IQR, 217-511]; P = .09), and at 1 year (median 269 pg/mL [IQR, 155-474] vs 133 pg/mL [IQR, 99-134]; P = .057). At NT-proBNP >480 pg/mL in the early period and >280 pg/mL at 1 year, LVH occurred with a 68% probability (P = .05 and P = .03, respectively). CONCLUSIONS: During the 1st year after RT, NT-proBNP levels decrease ≥2-fold and are primarily related to eGFR. NT-proBNP measurements are useful in identifying patients with LVH.
    [Abstract] [Full Text] [Related] [New Search]